Six compounds share a ‘recovery’ shelf. They belong to three research categories that use different models and measure different things, even though the biology they study overlaps in a living body.
When tissue is damaged, three things happen that are easy to run together: inflammatory signalling, immune-cell decisions, and the physical rebuilding of tissue. They are studied by different groups, in different models, with different endpoints. VIP, KPV, thymosin alpha-1, BPC-157, TB-500 and GHK-Cu each sit mainly in one of those categories. Sorting them is the first step in reading their evidence.
Inflammation research asks how cells produce and respond to inflammatory signals, and is often modelled by inducing colitis in mice or exposing cultured cells to an irritant, with cytokines and tissue damage as readouts. Immunology asks how immune cells decide what response to mount; its models are dendritic cells, T cells, infection challenges and, in people, conditions like chronic hepatitis. Tissue-repair research asks how blood supply is rebuilt, repair cells recruited and new fibres laid down; its models are cut tendons, skin wounds and ulcers, with strength, closure and structure as readouts.
A result in one category is not a result in another: reduced cytokines in a mouse colon do not show tendon strength, and a faster-closing ulcer does not show immune-cell signalling.
KPV is the three-amino-acid end of alpha-melanocyte-stimulating hormone, studied to test whether the hormone’s anti-inflammatory activity can be separated from its pigment effect. The main evidence is cultured intestinal cells and mice with chemically induced colitis, where KPV taken up through the transporter PepT1 reduced inflammatory signalling and tissue damage (Dalmasso et al. 2008). No human trial was identified. VIP, a 28-amino-acid messenger found in gut, blood vessels and nerves, protected the intestinal barrier in mice infected with a barrier-damaging bacterium (Conlin et al. 2009); its human trials, of the synthetic form aviptadil, were in lung conditions and answered narrow questions there.
Both are inflammation questions, mostly in rodent gut. Neither is a repair study.
Thymosin alpha-1 is a 28-amino-acid peptide from the thymus, the organ where T cells mature. Its research history is immune modulation: changing how immune cells respond, not making immunity ‘stronger’. In mouse dendritic cells and transplanted mice it signalled through Toll-like receptors, sensors that detect microbial patterns, and steered T helper cells towards a Th1 response (Romani et al. 2004). The human literature is condition-specific: the synthetic form, thymalfasin, in patients with chronic hepatitis B and certain cancers.
That is a question about coordination inside the immune system. It does not describe inflammation in a damaged tissue or the rebuilding that follows, and it is not evidence of general immune support in people without those conditions.
BPC-157 is a fifteen-amino-acid peptide studied almost entirely in rat injury models. The best-known experiment cut the Achilles tendon of rats and, with daily intraperitoneal injection from 30 minutes after surgery, measured load to failure, walking function and tissue structure over 14 days (Staresinic et al. 2003). No receptor is confirmed, human data are three small pilot studies (one an uncontrolled chart review that included BPC-157 with thymosin β4), and most of the literature comes from one affiliated group. GHK-Cu is the copper complex of a three-amino-acid plasma peptide. Its clearest human evidence is topical: a randomised, placebo-controlled trial of a GHK-Cu gel on diabetic foot ulcers reported greater closure and fewer infections (Mulder et al. 1994). That belongs to that gel, that wound and that route; no controlled human trial of a systemic route was identified.
These are repair questions with repair endpoints; they inform immune-cell direction or inflammatory signalling only where a study measured it. TB-500, full-length thymosin beta-4, sits here too, through its control of the actin scaffolding cells use to move, with a wound-healing literature of mouse and cell work plus small topical phase 2 trials in venous ulcers and dry eye (Goldstein et al. 2005).
Repair, inflammation and immunity interact in a living animal, which is why they get bundled. But the studies do not interact. Each compound above was tested in its own model with its own endpoint. The only published report of two of them given together is a small uncontrolled chart review of BPC-157 with thymosin β4 as separate knee injections; no controlled study has combined any of them. A reader who knows which category a compound sits in knows which questions its evidence can answer, which route and population the answer applies to, and which claims are simply borrowed from a neighbouring shelf.
Sources checked 2026-09-22